Read Time:8 Second
U.K. pharmaceutical giant GSK said the deal gives it the rights to develop, manufacture and commercialize messenger RNA-based candidate vaccines for flu and COVID-19.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
